Leandro Jonata Carvalho Oliveira, Medical Oncologist at Oncoclínicas Group, shared a post on LinkedIn about a paper he co-authored with colleagues published in JCO Global Oncology:
“Brazilian publication in JCO Journals evaluating the cost-effectiveness of Oncotype DX in the management of early RH+/HER2- breast cancer in supplementary health.
In a pharmacoeconomic modeling study, led by Ivan Zimmermann and Carlos Magliano, with the participation of colleagues from GBECAM, we showed that the use of the Oncotype DX genomic signature has the potential to increase patients’ quality of life (QALYs), reduce costs for the health system, and be cost-effective.
The gain in quality of life (QALYs) occurs through a better selection of patients who really benefit from chemotherapy: with a reduction in recurrence in high-risk patients and also a reduction in unnecessary treatment in low-risk patients.
In addition, the study shows the potential for cost reduction in practically all clinical scenarios evaluated.”
Title: Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector
Authors: Ivan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira, Marcia Gisele Santos da Costa, Tomás Reinert, Carlos Henrique dos Anjos, Daniela Rosa, Julio Araújo, Andrea Shimada, Daniele Assad-Suzuki, Marcelle Cesca, Max Mano, Gustavo Póvoa dos Santos, Sergio Cordeiro de Oliveira, Virginia Areal, Steve Millen
You can read the full article in JCO Global Oncology.
More posts featuring Leandro Jonata Carvalho Oliveira.